Pfizer Inc.’s proposed $160 billion merger with Allergan plc fizzled dramatically on Wednesday, after months of public anger and regulatory angst over the controversial tax inversion deal.
So why should Pfizer be thanking its lawyers?
The demise of a controversial tax inversion deal with Allergan may have frustrated Pfizer, but it doesn't leave the U.S. drug giant that much poorer.
April 06, 2016 at 08:27 PM
1 minute read
The original version of this story was published on The American Lawyer
Pfizer Inc.’s proposed $160 billion merger with Allergan plc fizzled dramatically on Wednesday, after months of public anger and regulatory angst over the controversial tax inversion deal.
So why should Pfizer be thanking its lawyers?
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS